Pharmaceuticals
Drug Manufacturers Eye Analytical Instrumentation to Reduce Operating Costs
SANTA CLARA, California, Dec. 12, 2019 /PRNewswire/ -- The total analytical instrumentation market in pharmaceuticals, biopharmaceuticals, and nutraceuticals generated revenues of $3.05 billion in 2018 and is expected to grow at aCAGR of 7.0% to touch $4.91 billion in 2025. Pharmaceuticals were t...
2019-12-12 23:11
383
HemoCue AB, the Pioneer and Global leader in Hemoglobin (Hb) Point-of-care Testing (POCT) to Further Strengthen National Activities in the Combat against Anemia in India
HemoCue AB report fruitful discussions, continued support and new activities related to health initiatives, following the participation at the High-Level Business Delegation inNew Delhi and Mumbai, on December 2-4, 2019 STOCKHOLM, Dec. 12, 2019 /PRNewswire/ -- In 2019, Sweden and India celebrate ...
2019-12-12 16:11
250
Human Microbiome Market to Reach $6.08 Billion by 2023, Powered by the High Growth in Over-the-Counter Probiotics
SANTA CLARA, California, Dec. 11, 2019 /PRNewswire/ -- There has been a surge in industry-academia collaborations in thehuman microbiome therapeutics space. The partnerships betweenpharma/biotech companies and academic institutes are bringing together the research expertise of educational organiz...
2019-12-11 23:55
335
GemVax announced phase II results of GV1001 for Alzheimer's disease treatment at CTAD 2019
SEOUL, South Korea, Dec. 11, 2019 /PRNewswire/ -- The 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 was held inSan Diego, USA, from December 4-7. At the CTAD, the results of various Alzheimer's disease clinical trials were shared, and it provided a glimpse into the possibility of treati...
2019-12-11 18:40
320
Xinhua Silk Road: E. China Nanjing Jiangbei New Area aims to develop life and health industry
BEIJING, Dec. 11, 2019 /PRNewswire/ -- Nanjing Jiangbei New Area, a state-level new area in East China'sJiangsu Province, is committed to building a 100 billion-yuan level life and health industrial cluster and becoming a gene city inChina. The news was announced by Luo Qun, a member of the Stan...
2019-12-11 16:52
326
CStone announces enrollment target reached in the global Phase III VOYAGER trial of avapritinib in Chinese patients with third-line GIST
SUZHOU, China, Dec. 11, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the on-going, global Phase III VOYAGER clinical trial of avapritinib, an investigational drug discovered by CStone's partner, Blueprint Medicines, has completed target ...
2019-12-11 11:00
306
AGC Biologics Expands Plasmid DNA Offering
SEATTLE, Dec. 11, 2019 /PRNewswire/ -- AGC Biologics, a global Contract Development and Manufacturing Organization (CDMO) for Biopharmaceuticals, is significantly expanding its CDMO services with plasmid DNA (pDNA) offerings from itsHeidelberg site in Germany. With the demand for pDNA growing rap...
2019-12-11 09:06
286
Kazia Initiates Preparatory Activities to Bring GDC-0084 into GBM AGILE, an International Phase II / III Study in Glioblastoma
SYDNEY, Dec. 11, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it's lead program, GDC-0084, has been selected to join GBM AGILE, an international, academic-led, multi-drug adaptive phase ...
2019-12-11 08:41
2441
Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at the 2019 ASH Annual Meeting
SUZHOU, China, Dec. 10, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today announced that th...
2019-12-10 16:00
475
CStone's anti-PD-L1 antibody demonstrates promising antitumor activity with a complete response rate of 33.3% and a good safety profile in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma
SUZHOU, China, Dec. 10, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) updated results from the CS1001-201 trial in a poster presentation at the 2019 American Society of Hematology (ASH) Annual Meeting. CS1001-201 trial is a single-arm, multicenter Phase II c...
2019-12-10 11:38
619
Townsville Hospital Treats First Australian Patient With Elekta Unity MR-Linac, a Transformative Approach to Precision Radiation Therapy
Ability to adapt daily treatment based on real-time MR imaging enables new approach to hard-to-treat cancers TOWNSVILLE, Australia, Dec. 10, 2019 /PRNewswire/ -- Elekta (EKTA-B.ST) today announced that Townsville Hospital inQueensland has treated the first patient in Australia using Elekta Unity ...
2019-12-10 08:13
3413
CStone appoints seasoned pharmaceutical executive Shirley Zhao as the General Manager for Greater China and Head of Commercial
SUZHOU, China, Dec. 6, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced the appointment of Ms.Shirley Zhao to the position of General Manager forGreater China and Head of Commercial. In this position, Ms. Zhao will be responsible for the commerci...
2019-12-06 18:53
843
Innovent Announces First Patient Dosed in Phase I Clinical Trial of Anti-LAG-3 Monoclonal Antibody in China
SUZHOU, China, Dec. 6, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today a...
2019-12-06 08:00
2334
Suvoda Secures $40M Investment from LLR Partners
Growth capital to support expansion of Suvoda's clinical trial software and services CONSHOHOCKEN, Pennsylvania, Dec. 5, 2019 /PRNewswire/ -- Suvoda LLC, a SaaS provider of clinical trial software, announced it secured a$40 million minority equity investment fromPhiladelphia-based private equity...
2019-12-05 17:00
402
Mayapada Clinic Accomplished Plenary Level Certification from the Accreditation Commission of the Ministry of Health
JAKARTA, Indonesia, Dec. 5, 2019 /PRNewswire/ -- Mayapada Clinic
2019-12-05 13:17
523
Biocon Biologics Takes Forward its Mission to Unlock Universal Access to Insulins Globally
BUSAN, South Korea, Dec. 5, 2019 /PRNewswire/ -- Biocon Biologics, a fully integrated 'pure play' global biosimilars organisation, is taking forward its mission of unlocking affordable access to quality insulins for people with diabetes across the world. As a credible, global insulins player, it ...
2019-12-05 09:00
451
FDA Grants Orphan Drug Designation to APR Applied Pharma Research's Investigational Drug for the Treatment of Epidermolysis Bullosa
BALERNA, Switzerland, Dec. 4, 2019 /PRNewswire/ -- APR Applied Pharma Research sa ("APR"), the Swiss pharma company focused in niche and rare therapeutic areas, announces that the US Food and Drug Administration (the "FDA") has granted Orphan Drug Designation for its investigational drug code-nam...
2019-12-04 19:22
408
Merck and Ping An Good Doctor Form Strategic Collaboration to Advance Intelligent Healthcare in China
SHANGHAI, Dec. 4, 2019 /PRNewswire/ -- Merck, a leading science and technology company, signed a strategic collaboration agreement today with one of the world's leading healthcare ecosystem platforms, Ping An Healthcare and Technology Company Limited (Stock code: "Ping An Good Doctor", 1833.HK)....
2019-12-04 12:57
4995
Continuing the Resplendence with 20 Years' Glory, CPhI China Welcomes the Golden Year of Chinese Pharma
SHANGHAI, Dec. 3, 2019 /PRNewswire/ -- As a world-renowned vertical trade and exchange event of the pharmaceutical industry, CPhI & P-MEC China 2020 will take place at Shanghai New International Expo Centre (SNIEC)June 22-24, 2020. The exhibition will reach a scale of 210,000m2, facilitate over 3...
2019-12-03 16:54
343
QBiotics Announces First Patient Dosed in its Phase I/II Clinical Trial of Tigilanol Tiglate for Head and Neck Cancer
* First patient successfully dosed in QBiotics' Phase I/II clinical trial of tigilanol tiglate in patients with Head and Neck Squamous Cell Carcinoma (HNSCC) * Tigilanol tiglate is a novel, small molecule that is being tested as a single injection treatment for solid tumours * The Phase I/II ...
2019-12-03 07:11
461
Week's Top Stories
Most Reposted
CapBridge, Dun & Bradstreet, and Singapore Commercial Credit Bureau Form Partnership to Provide Private Market Investors with Robust Information, Data, and Analytics
[Picked up by 124 media titles]
2019-12-11 14:03BRG Group Thrives in Vietnam's Golden Private Sector Era
[Picked up by 118 media titles]
2019-12-09 15:34
Research by Agoda shows that travelers are looking for "nature and scenery" which can be found in Jeju Island -- a great destination, even in winter
[Picked up by 109 media titles]
2019-12-10 13:03
Russell Reynolds Associates Hires Katherine Henry
[Picked up by 102 media titles]
2019-12-11 13:15
MOGUL.sg signs on Century 21, affirming its position as Singapore's Smartest Property Portal
[Picked up by 101 media titles]
2019-12-09 09:10Most Read
iQIYI Scream Night 2020 Sparks the Year's Entertainment Highlights
2019-12-08 10:08
4492
Forest City's international business complex Feathers of the Sea wins the 2019 Asian Townscape Jury's Award for the first time
2019-12-09 12:15
3877
Jianpu Technology Inc. Reports Third Quarter 2019 Unaudited Financial Results
2019-12-09 19:00
3782
China Online Education Group Announces Third Quarter 2019 Results
2019-12-09 18:23
3749
Ericsson Reaches Resolution on U.S. FCPA Investigations
2019-12-09 09:15
3685